Genia Dubrovsky

Dr. Genia Dubrovsky

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JAJurgis Alvikas
Jurgis Alvikas
SDShakti Dahiya
Shakti Dahiya
GDGenia Dubrovsky
Genia Dubrovsky
Post-operative pancreatic fistula (POPF) is a serious yet far too common complication following distal pancreatectomy (DP), as it affects 20–30% of patients after DP. POPF raises the risk of other complications and causes delays to a patient’s oncologic care. In this review, we present the latest data on patient risk factors for developing POPF, such as obesity, smoking, young age, thick pancreas, lack of epidural anesthesia, hypoalbuminemia, and elevated drain amylase levels. Other risk factors that have been identified with irregular consistency include open surgical approach, non-malignant or neuroendocrine tumor pathology, simultaneous splenectomy, simultaneous vascular resection, and long operative time. We also review the consequences of POPF, which include hemorrhage, infection, delayed gastric emptying, re-operation, re-admission, delays in adjuvant chemotherapy initiation, reduced progression-free survival, and reduced overall survival. Finally, we present strategies that have been studied for avoiding POPF after DP, including reducing pressure at the sphincter of Oddi, the use of sealants and patches, optimizing pancreatic transection, strategies for post-operative drain placement, the use of post-operative somatostatin analogues, and pre-clinical studies of experimental devices and techniques that may inform future trials. This review informs readers on the current state of the art with regard to POPF after DP and sets the stage for future studies to improve patient outcomes.

Verified
Journal Article
Open access
PDF file
GDGenia Dubrovsky
Genia Dubrovsky
ARAlison Ross
Alison Ross
PJPooya Jalali
Pooya Jalali
MLMichael Thomas Lotze
Michael Thomas Lotze
Pancreatic ductal adenocarcinoma (PDAC) remains a malignancy with one of the highest mortality rates. One limitation in the diagnosis and treatment of PDAC is the lack of an early and universal biomarker. Extensive research performed recently to develop new assays which could fit this role is available. In this review, we will discuss the current landscape of liquid biopsy in patients with PDAC. Specifically, we will review the various methods of liquid biopsy, focusing on circulating tumor DNA (ctDNA) and exosomes and future opportunities for improvement using artificial intelligence or machine learning to analyze results from a multi-omic approach. We will also consider applications which have been evaluated, including the utility of liquid biopsy for screening and staging patients at diagnosis as well as before and after surgery. We will also examine the potential for liquid biopsy to monitor patient treatment response in the setting of clinical trial development.

27 May 2025 in HPB
Verified
Journal Article
Open access
JAJurgis Alvikas
Jurgis Alvikas
AHAhmed Hamed
Ahmed Hamed
NTNikhil Tirukkovalur
Nikhil Tirukkovalur
SCSebastiaan Ceuppens
Sebastiaan Ceuppens
ATAdam Tcharni
Adam Tcharni
APAlessandro Paniccia
Alessandro Paniccia
CA 19-9 is the most commonly used biomarker for pancreatic ductal adenocarcinoma (PDAC) but prognostication is a challenge for patients with normal CA 19-9 levels. We aimed to define most important prognostic factors for overall survival in PDAC patients with normal range CA 19-9 levels. We performed a single-center retrospective review of PDAC patients with CA 19-9 level at diagnosis <37 U/mL who underwent curative intent resection. Cohort was divided into CA 19-9 non-producers (CA 19-9 level of <3 U/mL) and normal range CA 19-9 (between 3 U/mL and 37 U/mL). We used a multivariable Cox regression model to define the predictors of overall survival and constructed a nomogram. 271 patients were included (75 CA 19-9 non-producers and 196 with normal range CA 19-9). Non-producers had worse overall survival (27.2 months versus 33.6 months) and higher rate of recurrence after resection. Predictors of survival were CA 19-9 level, age, sex, lymph node ratio, perineural invasion, surgical margin status and adjuvant chemotherapy. PDAC patients who are CA 19-9 non-producers have worse survival. Our findings highlight this high-risk subgroup, identify useful prognostic features and emphasize the ongoing need for improved biomarker development.

31 January 2026 in Pancreatology
Verified
Journal Article
Open access
GDGenia Dubrovsky
Genia Dubrovsky
JQJiage Qian
Jiage Qian
SCSebastiaan Ceuppens
Sebastiaan Ceuppens
ACAsmita Chopra
Asmita Chopra
GNGeoffrey R. Nunns
Geoffrey R. Nunns
APAlessandro Paniccia
Alessandro Paniccia
Pancreaticoduodenectomy (PD) presents a surgical challenge, and its feasibility in patients on dialysis is debated due to concerns over heightened perioperative risks. This study employs the NSQIP pancreatectomy database to investigate the impact of dialysis on PD-specific postoperative complications. The NSQIP pancreatectomy targeted user file spanning 2014 to 2023 was used to identify patients undergoing a PD. Patients on dialysis were matched 1:3 to patients not receiving dialysis. Comparative analysis evaluated morbidity, mortality, and PD-specific complications. Among 43,565 patients who underwent a PD, 123 patients were on dialysis. Even after matching, dialysis patients displayed higher rates of complications, re-intubation, cardiac arrest, and bleeding (p < 0.001); furthermore, 30-day mortality was higher in the dialysis group (8.1% vs 3.0%, p = 0.014). However, rates of clinically relevant postoperative pancreatic fistula, delayed gastric emptying, and indwelling drain on POD 30 did not differ. Although dialysis patients undergoing PD face increased risks of mortality and complications, PD-specific complications were not affected. These findings offer valuable insights for patient counseling and surgeon awareness.

25 April 2025
Verified
Book Chapter
Closed access
GDGenia Dubrovsky
Genia Dubrovsky
NENoah Earland
Noah Earland
PHPeter Harris
Peter Harris
PCPradeep Chauhan
Pradeep Chauhan
JSJeff Szymanski
Jeff Szymanski
MLMichael Lotze
Michael Lotze

7 January 2026 in Lymphatics
Verified
Journal Article
Open access
PDF file
ARAlison Ross
Alison Ross
SDShakti Dahiya
Shakti Dahiya
PCPaulina Cabada
Paulina Cabada
MLMichael Thomas Lotze
Michael Thomas Lotze
JSJami L. Saloman
Jami L. Saloman
GDGenia Dubrovsky
Genia Dubrovsky
Diseases of the pancreas—such as pancreatic ductal adenocarcinoma (PDAC) and pancreatitis—have long been a challenge to treat. The study of lymphatics within the pancreas can provide some additional insights and offer new therapeutic targets. Here, we explore the development of pancreatic lymphatics and their connections to the nervous system and individual disease states, as well as the potential for therapeutic interventions. Lymphangiogenesis pathways in PDAC, driven by VEGF-C and other mediators, have been extensively explored, but specific therapeutic interventions are lacking. Furthermore, due to the emergence of PDAC with pancreatitis, insights could improve treatment in both settings. The role of neuroimmune interactions and control, as in other organ sites, appears as critical to both lymphatic and immune processes. With a better understanding of the lymphatic environment within the pancreas, we can develop more effective treatments for patients.